Cytokeratin 3 Activators
Cytokeratin 3 (CK3), also known as keratin 3 (KRT3), is a type II cytokeratin that is primarily expressed in the epithelial cells of the cornea, playing a pivotal role in maintaining corneal transparency and structural integrity. As a key component of the intermediate filament network in corneal epithelial cells, CK3 contributes to the mechanical resilience and protective barrier function of the cornea, essential for safeguarding the eye from environmental stressors, pathogens, and physical damage. The expression and organization of CK3, in conjunction with type I cytokeratins such as cytokeratin 12 (CK12), form the cytoskeletal framework that underpins the unique properties of the corneal epithelium. This structural arrangement is crucial for sustaining the clarity, refraction, and overall health of the cornea, ensuring optimal visual acuity.
The "activation" of CK3, in the context of cytokeratins, generally refers to the processes that regulate its expression, assembly, and organization within the intermediate filament network, rather than an enzymatic activation typical of other proteins. Regulation of CK3 expression is tightly controlled and responsive to both developmental cues and environmental conditions that the corneal epithelium encounters. Factors such as growth factors, cytokines, and cellular stress can influence CK3 expression levels, modulating the composition and dynamics of the intermediate filament network to adapt to changes in physiological or pathological conditions. Furthermore, post-translational modifications, including phosphorylation, can affect the assembly and disassembly dynamics of CK3-containing intermediate filaments, facilitating cellular remodeling, migration, and wound healing processes. These regulatory mechanisms ensure that CK3 function is optimally tuned to maintain corneal integrity, respond to injury, and support the renewal of the corneal epithelium, highlighting the sophisticated control of cytokeratin dynamics in epithelial tissue homeostasis and repair.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) is a potent activator of protein kinase C (PKC). Activation of PKC can lead to the phosphorylation of various cellular proteins, including those involved in cytoskeletal organization. PMA may influence Cytokeratin 3 indirectly by modulating signaling pathways that impact cytoskeletal dynamics. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, a derivative of vitamin A, can modulate gene expression by acting as a ligand for retinoic acid receptors (RARs). RARs, in turn, influence transcriptional programs involved in cellular differentiation. Retinoic acid may activate pathways leading to the expression or stabilization of factors affecting Cytokeratin 3 levels and promoting its cellular functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 mitogen-activated protein kinase (MAPK). Inhibition of p38 MAPK can lead to downstream effects on cellular processes, including cytoskeletal dynamics. SB203580 may indirectly activate Cytokeratin 3 by inhibiting pathways that negatively regulate its expression or function, resulting in enhanced cellular levels. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate is a histone deacetylase (HDAC) inhibitor, influencing chromatin structure and gene expression. Changes in gene expression may impact cellular processes, including those related to cytoskeletal organization. Sodium butyrate may modulate Cytokeratin 3 indirectly by altering the acetylation status of histones associated with its gene locus. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to an increase in intracellular cAMP levels. Elevated cAMP levels can modulate various cellular processes, including cytoskeletal dynamics. Forskolin may impact Cytokeratin 3 indirectly by influencing cAMP-dependent signaling pathways that regulate its expression or function. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that can elevate intracellular calcium levels. Increased calcium levels can influence various cellular processes, including those related to cytoskeletal dynamics. A23187 may impact Cytokeratin 3 indirectly by modulating calcium-dependent signaling pathways that regulate its expression or function in response to changes in intracellular calcium. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). ROCK signaling pathways are implicated in the regulation of cytoskeletal dynamics. By inhibiting ROCK, Y-27632 can indirectly activate Cytokeratin 3 by influencing the cellular responses to the Rho/ROCK pathway that intersect with cytoskeletal organization. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β type I receptor ALK5. Inhibition of ALK5 can affect TGF-β signaling pathways involved in cellular processes, including cytoskeletal organization. SB431542 may indirectly activate Cytokeratin 3 by inhibiting TGF-β pathways that negatively regulate its expression or function, resulting in enhanced cellular levels. | ||||||